Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5460 - A Pilot Study of Apatinib in Heavily Pretreated Metastatic adenocarcinoma of the Head and Neck

Date

10 Sep 2017

Session

Poster display session

Presenters

Lin Gui

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

L. Gui, X. He

Author affiliations

  • Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), 100021 - Beijing/CN
More

Resources

Abstract 5460

Background

Although antiangiogenic therapy is effiective in advanced lung, breast, renal, hepatic, and colon cancers, limited is known about its value in the cancer of the Head and Neck. Apatinib is an oral, highly potent tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). This prospective phase II study (NCT02989259) aims to investigate the efficacy and safety of apatinib in heavily pretreated patients (pts) with metastatic adenocarcinoma of the Head and Neck.

Methods

This study enrolled pts with metastatic adenocarcinoma of the Head and Neck, who failed in the metastatic setting at least one prior chemotherapy regimen. The primary end point of this study was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Patients were treated with apatinib 500 mg daily. Efficacy was assessed every 6 weeks.

Results

From December 2016, we recruited 10 pts, including 8 males and 2 females, with a median age of 53 years (26-71). Median number of previous chemotherapy regimens for the metastatic diseases was 2 (1-3). Median follow-up time was 4.3 months. 8 pts were eligible for efficacy analysis. ORR was 25% (2/8). DCR was 87.5% (7/8). Median PFS and median OS were not reached. The most common adverse events (AEs) of all grade were hypertension (n = 5), nausea (n = 4), fatigue (n = 4) and hand-foot syndrome (n = 3). The most common grade 3/4 AEs were hypertension (n = 2), thrombocytopenia (n = 1) and oral mucositis (n = 1). Toxicities were tolerable and manageable.

Conclusions

Our results so far indicated that apatinib exhibited objective efficacy in heavily pretreated, metastatic adenocarcinoma of the Head and Neck with acceptable safety.

Clinical trial identification

the trial protocol number: NCT02989259 release date: December 2016

Legal entity responsible for the study

The Institutional Review Board of the Cancer Institute/Hospital, CAMS & PUMC Institutional Review Board of the Cancer Institute/Hospital, CAMS & PUMC

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.